Pfizer Shares Plunge 3.31% as Volume Slumps to 46th in $1.58 Billion Activity Despite Strong Q2 Earnings and 20% Profit Margin

Pfizer (PFE) closed 2025-08-06 with a 3.31% decline, trading at $23.93 amid a 43.48% drop in trading volume to $1.58 billion, ranking 46th in market activity. The stock’s year-to-date return stands at -4.95%, lagging the S&P 500’s +7.88%.

The selloff followed Pfizer’s Q2 earnings report, which showed a 10% revenue increase to $14.7 billion and a 20% profit margin, surpassing analyst expectations. However, concerns persist over looming Trump-era pharmaceutical tariffs and potential price controls, as highlighted by CEO Albert Bourla during the earnings call. Bourla emphasized ongoing “productive discussions” with the government but warned of challenges from expiring drug patents and shifting market dynamics.

Analysts noted Pfizer’s cost-cutting initiatives and a robust pipeline, including oncology advancements post-Seagen acquisition, as long-term positives. However, near-term pressures from declining sales of pandemic-era products like Paxlovid and the mRNA vaccine, coupled with industry-wide tariff uncertainties, weigh on investor sentiment. The healthcare sector remains under pressure, with broader ETFs down 3.7% year-to-date.

A backtested strategy of purchasing top 500 high-volume stocks and holding for one day generated a 166.71% return from 2022 to 2025, outperforming the benchmark’s 29.18% by 137.53%. This highlights liquidity-driven strategies’ efficacy in volatile markets, where high-volume stocks often reflect strong short-term investor interest.